BRAF and melanoma: Importantly, MITFlowAXLhigh expression was shown to be common in BRAF mutated melanoma and has been identified in patients who relapsed following BRAF and MEK inhibitors treatment, thereby indicating that this signature results in a drug resistant phenotype (50).